A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

This study has been terminated.
(Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.)
Sponsor:
Information provided by (Responsible Party):
Ronald Buckanovich, University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT00637390
First received: March 10, 2008
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

Ovarian cancer cannot grow without recruiting new blood vessels. Studies in humans have identified a novel cell population, termed vascular leukocytes (VLCs). While VLCs are not cancer cells, they support the growth of ovarian cancer cells by stimulating the growth of new blood vessels which provide the cancer with nutrients. VLCs make a protein termed CD52. An antibody therapeutic, Alemtuzumab (also know as Campath), that kills cells that make the CD52 protein has been successfully used to treat certain lymphomas (a type of blood cell cancer) that make CD52 protein. The purpose of this study is to determine if Alemtuzumab given subcutaneously (under the skin)can be safely given to patients with ovarian, fallopian, or primary peritoneal cancers to kill VLCs and determine if Alemtuzumab, by eliminating VLCs, can restrict tumor growth or increase response rates to chemotherapy given after the discontinuation of chemotherapy.


Condition Intervention Phase
Ovarian, Fallopian or Primary Peritoneal Cancer.
Drug: Alemtuzumab
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Resource links provided by NLM:


Further study details as provided by University of Michigan Cancer Center:

Primary Outcome Measures:
  • safety & maximally tolerated dose [ Time Frame: Maybe 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Effectiveness of Alemtuzumab to eliminate VLCs. [ Time Frame: Maybe 2 years ] [ Designated as safety issue: No ]
  • Assess molecular markers associated with reduction in VLCs. [ Time Frame: Maybe 2 years ] [ Designated as safety issue: No ]
  • Anti-tumor activity measured by decline or stabilization of CA125(a protein that is a tumor marker)or radiological(ie. CT, MRI, X-Ray)improvement or improvement in progression free survival. [ Time Frame: Maybe 2 years ] [ Designated as safety issue: No ]
  • Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy. [ Time Frame: Maybe 2 years ] [ Designated as safety issue: No ]

Enrollment: 3
Study Start Date: March 2008
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: one Drug: Alemtuzumab
will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have a diagnosis of histologically confirmed ovarian, fallopian or primary peritoneal cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy as documented by either:

    1. Radiologic studies or
    2. Rising CA125 levels on two independent measurements. If the patient's CA125 has fallen into a normal range, CA125 relapse will be defined as double the nadir CA125. However, if the patients CA125 nadir had fallen to less than 10, then the measurements documenting recurrence or progression must be greater than 20.
  2. There is no limit on prior courses of chemotherapy.
  3. Patients must have unidimensional measurable disease or elevated CA125
  4. Age greater than 18 years.
  5. ECOG performance status less tha 2 (Karnofsky 60%).
  6. Life expectancy of greater than 12 weeks.
  7. Patients must have adequate organ and marrow function
  8. Ability to understand and the willingness to sign a written informed consent document. All patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines.
  9. Timing guideline for pre-study labs and measurements:

All pre-study labs required for determination of eligibility are to be completed within 28 days of treatment Day 1.

X-rays and/or scans used for tumor measurement to determine disease status are to be completed within 28 days of treatment Day 1.

Women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

  1. Patients with known immunosuppressive diseases are excluded from this trial due to the known immunosuppressive nature of Alemtuzumab therapy.
  2. Patients may not be receiving any other agents (investigational or otherwise) with therapeutic intent.
  3. Patients with prior malignancy, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for 2 years.
  4. Patients with a history of allergic reactions to Alemtuzumab or other humanized immunotherapeutics.
  5. Patients with unresolved bacterial, fungal, or viral infections requiring active treatment. Patients may be registered two weeks after the conclusion of antibiotic or anti-viral therapy.
  6. Patients with history of active CMV disease as Alemtuzumab therapy has been associated with CMV reactivation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00637390

Locations
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
Ronald Buckanovich
  More Information

No publications provided

Responsible Party: Ronald Buckanovich, Professor of Internal Medicine, University of Michigan Cancer Center
ClinicalTrials.gov Identifier: NCT00637390     History of Changes
Other Study ID Numbers: UMCC 2007.120
Study First Received: March 10, 2008
Last Updated: June 18, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Peritoneal Neoplasms
Abdominal Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Alemtuzumab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 18, 2014